News articles about Intellia Therapeutics (NASDAQ:NTLA) have trended positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intellia Therapeutics earned a news impact score of 0.27 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.384673033308 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- Analyzing Alkermes (ALKS) & Intellia Therapeutics (NTLA) (americanbankingnews.com)
- Focus on Technical Insights: Intellia Therapeutics Inc. (NTLA) – Wall Street Morning (wallstreetmorning.com)
- Intellia Therapeutics Inc., (NASDAQ: NTLA) – Is Stock’s Performance Impressive? – Stock Watch (stocksnewstimes.com)
- Intraday Trade Strategies in Focus – Intellia Therapeutics Inc (NASDAQ: NTLA) – Alpha Beta Stock (alphabetastock.com)
NTLA has been the subject of several research reports. Credit Suisse Group lifted their price target on Intellia Therapeutics from $24.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, November 3rd. Jefferies Group set a $42.00 price target on Intellia Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 31st. Leerink Swann lifted their price target on Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Oppenheimer reiterated a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, December 12th. Finally, BidaskClub raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $30.17.
In related news, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total value of $27,870,900.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Nessan Bermingham sold 111,500 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $20.34, for a total value of $2,267,910.00. Following the completion of the transaction, the chief executive officer now directly owns 696,000 shares in the company, valued at $14,156,640. The disclosure for this sale can be found here. Insiders sold a total of 2,521,928 shares of company stock worth $51,883,434 over the last three months. 12.80% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Intellia Therapeutics (NTLA) Given Daily Media Sentiment Score of 0.27” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/02/21/intellia-therapeutics-ntla-given-daily-media-sentiment-score-of-0-27.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.